Effects of on Tumor Microenvironment and Immunotherapy Responses

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Aug 15

PMID 35967444

Authors

Ruiyi Deng

Huiling Zheng

Hongzhen Cai

Man Li

Yanyan Shi

Shigang Ding

Affiliations

Soon will be listed here.

Abstract

is closely associated with gastric cancer. During persistent infection, can form a microenvironment in gastric mucosa which facilitates the survival and colony formation of . Tumor stromal cells are involved in this process, including tumor-associated macrophages, mesenchymal stem cells, cancer-associated fibroblasts, and myeloid-derived suppressor cells, and so on. The immune checkpoints are also regulated by infection. virulence factors can also act as immunogens or adjuvants to elicit or enhance immune responses, indicating their potential applications in vaccine development and tumor immunotherapy. This review highlights the effects of on the immune microenvironment and its potential roles in tumor immunotherapy responses.

Citing Articles

BTK inhibitors are a possible emerging therapeutic target for gastric cancer.

Portillo-Mino J, Calderon J, Riquelme A Mol Ther Oncol. 2025; 33(1):200935.

PMID: 39990595 PMC: 11846545. DOI: 10.1016/j.omton.2025.200935.

Cancer vaccine designed from homologous ferritin-based fusion protein with enhanced DC-T cell crosstalk for durable adaptive immunity against tumors.

Wu J, Liang J, Li S, Lu J, Li Y, Zhang B Bioact Mater. 2025; 46:516-530.

PMID: 39868073 PMC: 11764028. DOI: 10.1016/j.bioactmat.2024.12.029.

Evaluation of the relationship between infected gastric mucosa and prognosis of gastrointestinal stromal tumor.

Herdan R, Taher M, Shafiq A, Omran O, Abozaid L, Babiker N Int J Health Sci (Qassim). 2025; 19(1):41-48.

PMID: 39760053 PMC: 11699233.

The paradox of : how does infection protect against esophageal cancer?.

Banisefid E, Nasiri E, Pourebrahimian Leilabadi S, Hamzehzadeh S, Akbarzadeh M, Hosseini M Ann Med Surg (Lond). 2024; 86(12):7221-7226.

PMID: 39649904 PMC: 11623814. DOI: 10.1097/MS9.0000000000002674.

Role and value of the tumor microenvironment in the progression and treatment resistance of gastric cancer (Review).

Yun H, Dong F, Wei X, Yan X, Zhang R, Zhang X Oncol Rep. 2024; 53(1).

PMID: 39611496 PMC: 11622107. DOI: 10.3892/or.2024.8847.

References

Gambardella V, Castillo J, Tarazona N, Gimeno-Valiente F, Martinez-Ciarpaglini C, Cabeza-Segura M . The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target. Cancer Treat Rev. 2020; 86:102015. DOI: 10.1016/j.ctrv.2020.102015. View

Yaghoobi M . Bone Marrow-Derived Stem Cells in Pathogenesis of Helicobacter Pylori-Associated Gastric Cancer. Clin Transl Gastroenterol. 2015; 6:e110. PMC: 5176315. DOI: 10.1038/ctg.2015.35. View

Xue L, Mao X, Liu X, Gao H, Chen Y, Dai T . Activation of CD3 T cells by Helicobacter pylori DNA vaccines in potential immunotherapy of gastric carcinoma. Cancer Biol Ther. 2019; 20(6):866-876. PMC: 6605983. DOI: 10.1080/15384047.2019.1579957. View

Hinshaw D, Shevde L . The Tumor Microenvironment Innately Modulates Cancer Progression. Cancer Res. 2019; 79(18):4557-4566. PMC: 6744958. DOI: 10.1158/0008-5472.CAN-18-3962. View

Houghton J, Stoicov C, Nomura S, Rogers A, Carlson J, Li H . Gastric cancer originating from bone marrow-derived cells. Science. 2004; 306(5701):1568-71. DOI: 10.1126/science.1099513. View

Senchukova M, Tomchuk O, Shurygina E . in gastric cancer: Features of infection and their correlations with long-term results of treatment. World J Gastroenterol. 2021; 27(37):6290-6305. PMC: 8515796. DOI: 10.3748/wjg.v27.i37.6290. View

Peng X, Zhang R, Duan G, Wang C, Sun N, Zhang L . Production and delivery of Helicobacter pylori NapA in Lactococcus lactis and its protective efficacy and immune modulatory activity. Sci Rep. 2018; 8(1):6435. PMC: 5915382. DOI: 10.1038/s41598-018-24879-x. View

Alfaro C, Teijeira A, Onate C, Perez G, Sanmamed M, Andueza M . Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs). Clin Cancer Res. 2016; 22(15):3924-36. DOI: 10.1158/1078-0432.CCR-15-2463. View

Smyth E, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D . Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016; 27(suppl 5):v38-v49. DOI: 10.1093/annonc/mdw350. View

10.

Panagioti E, Kurokawa C, Viker K, Ammayappan A, Anderson S, Sotiriou S . Immunostimulatory bacterial antigen-armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy. J Clin Invest. 2021; 131(13). PMC: 8245183. DOI: 10.1172/JCI141614. View

11.

Muro K, Chung H, Shankaran V, Geva R, Catenacci D, Gupta S . Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 2016; 17(6):717-726. DOI: 10.1016/S1470-2045(16)00175-3. View

12.

Darvin P, Toor S, Sasidharan Nair V, Elkord E . Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018; 50(12):1-11. PMC: 6292890. DOI: 10.1038/s12276-018-0191-1. View

13.

Arcucci A, Ruocco M, Granato G, Sacco A, Montagnani S . Cancer: An Oxidative Crosstalk between Solid Tumor Cells and Cancer Associated Fibroblasts. Biomed Res Int. 2016; 2016:4502846. PMC: 4993917. DOI: 10.1155/2016/4502846. View

14.

Wesolowski R, Markowitz J, Carson 3rd W . Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer. J Immunother Cancer. 2014; 1:10. PMC: 4019895. DOI: 10.1186/2051-1426-1-10. View

15.

Koh V, Chakrabarti J, Torvund M, Steele N, Hawkins J, Ito Y . Hedgehog transcriptional effector GLI mediates mTOR-Induced PD-L1 expression in gastric cancer organoids. Cancer Lett. 2021; 518:59-71. PMC: 8606306. DOI: 10.1016/j.canlet.2021.06.007. View

16.

Codolo G, Fassan M, Munari F, Volpe A, Bassi P, Rugge M . HP-NAP inhibits the growth of bladder cancer in mice by activating a cytotoxic Th1 response. Cancer Immunol Immunother. 2011; 61(1):31-40. PMC: 11028894. DOI: 10.1007/s00262-011-1087-2. View

17.

Ding C, Li L, Zhang Y, Ji Z, Zhang C, Liang T . Toll-like receptor agonist rMBP-NAP enhances antitumor cytokines production and CTL activity of peripheral blood mononuclear cells from patients with lung cancer. Oncol Lett. 2018; 16(4):4707-4712. PMC: 6126164. DOI: 10.3892/ol.2018.9182. View

18.

Kono K, Nakajima S, Mimura K . Current status of immune checkpoint inhibitors for gastric cancer. Gastric Cancer. 2020; 23(4):565-578. DOI: 10.1007/s10120-020-01090-4. View

19.

El-Zaatari M, Kao J, Tessier A, Bai L, Hayes M, Fontaine C . Gli1 deletion prevents Helicobacter-induced gastric metaplasia and expansion of myeloid cell subsets. PLoS One. 2013; 8(3):e58935. PMC: 3592845. DOI: 10.1371/journal.pone.0058935. View

20.

Ramachandran M, Yu D, Wanders A, Essand M, Eriksson F . An infection-enhanced oncolytic adenovirus secreting H. pylori neutrophil-activating protein with therapeutic effects on neuroendocrine tumors. Mol Ther. 2013; 21(11):2008-18. PMC: 3831034. DOI: 10.1038/mt.2013.153. View